Axcan May Ax Itax Program For Functional Dyspepsia After Phase III Fails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Axcan's decision on whether to abandon Itax (itopride) development for functional dyspepsia will await further analysis of a failed international Phase III trial and results of a second Phase III study due in June